Studies have indicated that in the general population, lower adiponectin levels are linked to insulin resistance, type 2 diabetes mellitus (DM), and coronary artery disease (CAD) [11–13], which are conditions that may contribute to CKD development. Here, ADIPOQ is linked to chronic kidney disease.